Charité Comprehensive Cancer Center, Berlin, Germany
Sebastian Ochsenreither , Ulrich Keilholz , Konrad Friedrich Klinghammer , Christina Dicke , Maxim Kebenko , Elena Garralda , Josep Tabernero , Ignacio Matos , Domenica Lorusso , Francesco Raspagliesi , Luca Gianni , Gianluca Del Conte , Beate Habel , Hans Baumeister , Riccardo Belli , Alfredo Zurlo , Walter M. Fiedler
Background: TO (CetuGEX) is a second-generation anti-EGFR antibody that specifically binds to EGFR and acts as a competitive antagonist at the ligand binding site. GAT (PankoMab-GEX) is a novel humanized monoclonal antibody, which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1) expressed on tumor cells. Both antibodies are glyco-engineered to potentiate antibody-dependent cellular cytotoxicity (ADCC). Compelling preclinical evidence suggests a complex interaction between EGFR and cell surface expressed TA-MUC1 in driving cancerogenesis processes as well as shows a synergistic ADCC activity with the dual targeting of these molecules. Based on this evidence, this study aims to assess the tolerability, safety and preliminary activity of a combination with anti-EGFR and anti-TA-MUC1 glyco-engineered antibodies. Methods: The GATTO is an open label phase Ib dose evaluation study in patients with EGFR positive metastatic solid tumors, for whom no standard treatment is available. The proposed doses and schedule are 1400 mg Q2W for GAT and 1200 mg Q2W for TO. A staggered approach will be utilized in order to minimize the number of patients exposed and to evaluate the safety of the combination treatment. The first 6 patients will be enrolled into a safety run-in phase where the number of dose-limiting toxicities (DLTs) will be evaluated. Assuming that the safety criteria are met (ie. observation of 0 or 1 DLT), the dose will remain unchanged and further patients will be recruited at this dose level. If this is not the case, a step-wise dose reduction approach will be applied. The antitumor activity of the combined treatment will be evaluated as secondary endpoints including best overall response rate (ORR), duration of objective response, progression-free (PFS) and overall (OS) survival. Extensive pharmacokinetics (PK) and pharmacodynamics (PD) (cellular immune status, serum and tissue biomarkers) will be also analyzed. As of January 2018, the study is ongoing and 2 patients have been treated. (ClinicalTrials.gov Identifier: NCT03360734). Clinical trial information: NCT03360734
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2019 ASCO Annual Meeting
First Author: Emiliano Calvo
2023 ASCO Genitourinary Cancers Symposium
First Author: Monika Joshi
2022 ASCO Annual Meeting
First Author: Anna Maria Di Giacomo
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Jessica Dreger McDermott